Micofenolato De Mofetilo Sandoz

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Sandoz, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune conditions such as lupus nephritis.

GNH USA supplies Micofenolato De Mofetilo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in immunosuppressive regimens for transplant and autoimmune disease management. - Organ transplant rejection: helps prevent graft rejection by suppressing the immune response. - Lupus nephritis: reduces kidney inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases: provides disease control in selected cases such as certain vasculitides when other therapies are insufficient.

Mycophenolate Mofetil may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Headache: occasional tension‑type headache. - Abdominal pain: cramping or discomfort. - Tremor: fine shaking of hands.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring medical attention. - Leukopenia or lymphopenia: marked reduction in white blood cells. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers with long‑term use.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dosing in patients with impaired kidney function. - Avoid live vaccines: immunosuppression can lead to vaccine‑derived infection. - Pregnancy: Category D; use only when benefits outweigh potential fetal risks. - Infection risk: counsel patients to report fever, cough, or unusual infections promptly. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Mycophenolate Mofetil interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Live vaccines: heightened risk of infection. - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce mycophenolate exposure. - Antacids containing aluminum or magnesium: decrease oral absorption.

Moderate Interactions (Monitor Closely): - Calcineurin inhibitors (cyclosporine, tacrolimus): may increase mycophenolate plasma levels. - Antifungal azoles (ketoconazole, fluconazole): can raise exposure and risk of toxicity. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.